

Veozah[®] (fezolinetant) – Boxed warning added

- On December 16, 2024, the <u>FDA approved</u> a label update to Astellas' <u>Veozah (fezolinetant)</u>, adding a Boxed Warning for the risk of hepatotoxicity.
 - In September 2024, the FDA added a warning about the risk of liver injury and required liver blood testing in the prescribing information for Veozah. The new update elevates this risk to a *Boxed Warning*, which is the FDA's most prominent warning.
- The FDA update was based on a review of a post marketing report of a patient with elevated liver blood test values and signs and symptoms of liver injury after taking the medicine for about 40 days.
- Veozah is a neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Healthcare professionals should conduct **hepatic laboratory testing before prescribing Veozah**, then every month for the first three months after patients start treatment, and then at months 6 and 9 of treatment.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.